Compounds of Formula I are disclosed

##STR00001##

As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Compounds of Formula I are disclosed

##STR00001##

As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Compounds of Formula I are disclosed ##STR00001## As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.j, R.sup.k, and Q are as defined herein.

##STR00001##

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.j, R.sup.k, and Q are as defined herein.

##STR00001##

A compound of formula (I) as Bruton's tyrosine kinase inhibitor, a preparation method therefor, and an application thereof in the field of medicine. The Bruton's tyrosine kinase inhibitor may be used for preventing and/or treating a disease related to Bruton's tyrosine kinase mediation, such as an autoimmune disease, cancer, or an inflammatory disease. Through experimental research, the provided compound has high selectivity with respect to a Bruton's tyrosine kinase target, and can exhibit a uniquely advantageous medicinal effect in an in vivo animal experiment. ##STR00001##